Self SG - Search Results

1

A framework for assessing immunological correlates of protection in vaccine trials.

Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. Qin L, et al. Among authors: self sg. J Infect Dis. 2007 Nov 1;196(9):1304-12. doi: 10.1086/522428. Epub 2007 Oct 2. J Infect Dis. 2007. PMID: 17922394

2

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC. Gilbert P, et al. Among authors: self sg. J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816. J Infect Dis. 2010. PMID: 20608874 Free PMC article. Clinical Trial.

3

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network. Montefiori DC, et al. J Infect Dis. 2004 Dec 1;190(11):1962-9. doi: 10.1086/425518. Epub 2004 Oct 28. J Infect Dis. 2004. PMID: 15529261

4

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. Among authors: self sg. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

5

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: self sg. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

6

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. Among authors: self sg. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

7

On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.

Wick WD, Gilbert PB, Self SG. Wick WD, et al. Among authors: self sg. PLoS Comput Biol. 2006 Jun 16;2(6):e64. doi: 10.1371/journal.pcbi.0020064. Epub 2006 Jun 16. PLoS Comput Biol. 2006. PMID: 16789816 Free PMC article.

8

Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Gilbert PB, Qin L, Self SG. Gilbert PB, et al. Among authors: self sg. Stat Med. 2008 Oct 15;27(23):4758-78. doi: 10.1002/sim.3122. Stat Med. 2008. PMID: 17979212 Free PMC article.

9

Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Gilbert PB, Qin L, Self SG. Gilbert PB, et al. Among authors: self sg. Stat Med. 2009 Feb 15;28(4):716-9. doi: 10.1002/sim.3503. Stat Med. 2009. PMID: 19140113 Free PMC article.

10

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG. Gilbert PB, et al. Among authors: self sg. Stat Commun Infect Dis. 2011 Oct;3(1):1037. doi: 10.2202/1948-4690.1037. Stat Commun Infect Dis. 2011. PMID: 23181167 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page